Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals3.41%-0.36 ppManaged Health Care1.27%-0.36 ppHealth Care Equipment1.95%-0.35 ppLife Sciences Tools & Services1.09%-0.18 ppBiotechnology1.60%-0.16 ppHealth Care Services0.42%-0.08 ppHealth Care Technology0.02%+0.02 ppHealth Care Facilities0.17%-0.01 ppHealth Care Supplies0.12%-0.01 ppHealth Care Distributors0.29%-0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.60%
Industry change · 12M
-0.16 pp
Biotechnology · contribution
-0.163 pp
Company participation
0%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
May 2024 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Gilead Sciences → GILD | United States | $80.1bn | 0.153% | -0.104 pp | -0.084 pp | -13.2% | No |
| AbbVie → ABBV | United States | $284.7bn | 0.544% | -0.347 pp | -0.057 pp | +21.6% | No |
| Biogen → BIIB | United States | $32.8bn | 0.063% | -0.028 pp | -0.043 pp | -24.1% | No |
| Amgen → AMGN | United States | $164.1bn | 0.314% | -0.107 pp | +0.022 pp | +42.9% | No |
| Vertex Pharmaceuticals → VRTX | United States | $117.5bn | 0.225% | -0.087 pp | +0.019 pp | +40.7% | No |
| Moderna → MRNA | United States | $54.6bn | 0.104% | +0.003 pp | -0.016 pp | +11.6% | No |
| Incyte → INCY | United States | $13.0bn | 0.025% | -0.013 pp | -0.009 pp | -6.1% | No |
| Regeneron Pharmaceuticals → REGN | United States | $92.1bn | 0.176% | -0.084 pp | +0.005 pp | +33.3% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.